Plasma Kinins Increase after Angiotensin-Converting Enzyme Inhibition in Human Subjects
The DOI matches its Crossref record.
Abstract
1. In patients treated with angiotensin-converting enzyme inhibitors, kinin-related effects have been postulated repeatedly, but information on changes in plasma kinin levels in these patients is sparse. Difficulties in the measurement of plasma kinins account for this, at least in part. 2. The main purpose of the present study was to investigate, in normal human subjects, the effect of the angiotensin-converting enzyme inhibitor quinapril on plasma kinins. 3. High-affinity antisera (Kd <10−11 mol/l) of C-terminal specificity were raised in rabbits for radioimmunoassay of immunoreactive kinins activating the bradykinin B2-receptor, and three different liquid-and solid-phase extraction methods for plasma kinins were evaluated. Ethanol and subsequent petroleum ether extraction of 5–40 fmol of bradykinin added to plasma yielded recoveries of 39 ± 16% (mean ± SD); normal kinin levels in human plasma were 18.6 ± 3.3 pmol/l (mean ± SEM). Solid-phase extraction on urea-equilibrated phenylsilylsilica produced recoveries of 89 ± 5% and normal values of 36.4 ± 18 pmol/l. Finally, with an assay based on ethanol extraction alone, recoveries of 100 ± 16% and normal values of 16.8 ± 5.8 pmol/l were obtained, with a detection limit of 1.5 fmol/ml of plasma. Blanks were below the detection limit. Serial dilution of plasma extracts (n = 4) provided linear kinin concentrations (r = 0.99). For two different plasma pools, coefficients of variation for within-assay precision were 16.7% and 21.7%, respectively. Between-assay coefficients of variation were 12.8% and 17.4%. 4. After an oral quinapril dose of 20 mg, we found, in nine healthy men, an increase in plasma kinin levels from 16.1 ± 1.9 pmol/1 (mean ± SEM) to 22.4 ± 2.8, 23.9 ± 23, 29.1 ± 4.7 (P < 0.05) and 203 ± 4.2 pmol/1 at 2, 4, 8 and 24 h after drug intake, respectively. 5. Thus, in normal subjects treated with angiotensin-converting enzyme inhibitor plasma levels of B2-receptor stimulating kinins increase.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Plasma bradykinin in angio-oedema
Nussberger, J., Cugno, M., Amstutz, C., Cicardi, M., Pellacani, A., & Agostoni, A. (1998) · The Lancet · doi:10.1016/s0140-6736(97)09137-x · Cited by 706
Self-citationCicardi, M., Aberer, W., Banerji, A., Bas, M., Bernstein, J. A., Bork, K., Caballero, T., Farkas, H., Grumach, A., Kaplan, A. P., et al. (2014) · Allergy · doi:10.1111/all.12380 · Cited by 666
Hornig, B., Kohler, C., & Drexler, H. (1997) · Circulation · doi:10.1161/01.cir.95.5.1115 · Cited by 333
Angiotensin-converting enzyme inhibitor fetopathy.
Pryde, P. G., Sedman, A. B., Nugent, C. E., & Barr, M. (1993) · Journal of the American Society of Nephrology · doi:10.1681/asn.v391575 · Cited by 332
Bradykinin and the pathophysiology of angioedema
Cugno, M., Nussberger, J., Cicardi, M., & Agostoni, A. (2003) · International Immunopharmacology · doi:10.1016/s1567-5769(02)00162-5 · Cited by 215
Self-citationDrug-Induced Angioedema without Urticaria: Incidence, Prevention and Management
Agostoni, A., & Cicardi, M. (2001) · Drug Safety · doi:10.2165/00002018-200124080-00004 · Cited by 154
Angioedema due to angiotensin-converting enzyme inhibitors
Agostoni, A., Cicardi, M., Cugno, M., Zingale, L. C., Gioffré, D., & Nussberger, J. (1999) · Immunopharmacology · doi:10.1016/s0162-3109(99)00107-1 · Cited by 147
Self-citationThe kallikrein-kininogen-kinin system: lessons from the quantification of endogenous kinins
Blais, C., Marceau, F., Rouleau, J.-L., & Adam, A. (2000) · Peptides · doi:10.1016/s0196-9781(00)00348-x · Cited by 135
Metadata
- Authors
- Pellacani, A., Brunner, H. R., & Nussberger, J.
- Venue
- Clinical Science
- Publisher
- Portland Press Ltd.
- Published
- 1994-11-01
- Volume
- 87
- Issue
- 5
- Pages
- 567-574
- ISSN
- 0143-5221 (ISSN-L)
- 1470-8736
- OpenAlex
- W2418942964
- Cited by
- 133
- References
- 0
- FWCI
- 4.02
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.